Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225550 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors
A Phase 1 study, sponsored by Adherex Technologies.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00225550 is a Phase 1 study that was terminated before completion, run by Adherex Technologies.
The verdict
NCT00225550, a Phase 1 study, was terminated before completion, sponsored by Adherex Technologies.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that subjects can tolerate.
Interventions
- DRUG ADH -1 (Exherin™)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225550
The ClinicalTrials.gov registry entry for NCT00225550 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Adherex Technologies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADH -1 (Exherin™) is the first listed.
NCT00225550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00225550 about?
NCT00225550 is a clinical study titled "A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors". N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin...
What is the current status of trial NCT00225550?
This trial is currently terminated. It is a Phase 1 study.
What interventions are being tested in trial NCT00225550?
The interventions under investigation include: ADH -1 (Exherin™) (DRUG).
Who is sponsoring clinical trial NCT00225550?
This trial is sponsored by Adherex Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.